Public Profile

Regeneron

Regeneron Pharmaceuticals, Inc., commonly referred to as Regeneron, is a leading biotechnology company headquartered in the United States. Founded in 1988, Regeneron has established itself as a pioneer in the development of innovative medicines, particularly in the fields of ophthalmology, oncology, and immunology. With a strong focus on research and development, Regeneron is renowned for its unique products, including EYLEA® for eye diseases and Dupixent® for various allergic conditions. The company’s commitment to scientific excellence has positioned it as a key player in the biopharmaceutical industry, achieving significant milestones such as the rapid development of treatments during public health emergencies. Regeneron continues to expand its global footprint, with major operations across North America and Europe, solidifying its reputation as a leader in advancing healthcare solutions.

DitchCarbon Score

How does Regeneron's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

59

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

Regeneron's score of 59 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.

94%

Let us know if this data was useful to you

Regeneron's reported carbon emissions

In 2024, Regeneron reported total greenhouse gas emissions of approximately 1,465,520,000 kg CO2e, comprising 80,300,000 kg CO2e from Scope 1, 40,400,000 kg CO2e from Scope 2 (market-based), and a significant 1,344,820,000 kg CO2e from Scope 3 emissions. The company has set ambitious targets to reduce its carbon footprint, aiming for a 30% reduction in combined Scope 1 and 2 emissions per square metre by 2025, using a 2016 peak baseline as a reference. In 2023, Regeneron's total emissions were approximately 972,376,000 kg CO2e, with Scope 1 emissions at 69,600,000 kg CO2e, Scope 2 emissions (market-based) at 29,900,000 kg CO2e, and Scope 3 emissions reaching 872,876,000 kg CO2e. The company has committed to matching 100% of its electricity consumption with certified renewable energy sources by 2035, which will apply to both Scope 1 and Scope 2 emissions. Regeneron's emissions intensity has shown a trend of improvement, with a reported intensity of 210 kg CO2e per square metre for Scope 1 and 2 emissions in 2024. The company continues to disclose its emissions data transparently, aligning with industry standards and climate commitments.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

201620172018201920202021202220232024
Scope 1
39,400,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 2
25,300,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
00,000,000
Scope 3
288,800,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. Regeneron's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for Regeneron is in US, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

Regeneron is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

MERCK Kommanditgesellschaft auf Aktien

DE
Pharmaceutical Preparation Manufacturing
Updated 7 days ago

STADA Arzneimittel Aktiengesellschaft

DE
Pharmaceutical Preparation Manufacturing
Updated 9 days ago

Allergan

US
Pharmaceutical Preparation Manufacturing
Updated 23 days ago

Boehringer Ingelheim International GmbH

DE
Pharmaceutical Preparation Manufacturing
Updated 11 days ago

Novartis

CH
Pharmaceutical Preparation Manufacturing
Updated 1 day ago

Genmab

DK
Medical, precision and optical instruments, watches and clocks (33)
Updated 23 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers